Moderna’s shot is the third RSV vaccine for people 60 and older that’s gotten the green light from the FDA and the first mRNA vaccine among them. It’s the company’s second product to receive FDA approval, behind its Covid-19 vaccine.
The surge in RSV cases following the COVID-19 pandemic may have been, in part, caused by increased testing and changes to the RSV genome, according to a Northwestern Medicine study published in Nature Communications.
More needs to be done to ensure migrant communities are a key focus of receiving vital routine vaccinations to ensure health equity. That is according to Dr. Sally Hargreaves from St George's, University of London, whose research is published as part of the new migrant health Series in The Lancet Regional Health—Europe and is speaking at a World Health Assembly side event at The Geneva Health Forum.
